Promising Response Data for Menin Inhibitor in Relapsed/Refractory AML

(MedPage Today) — HOUSTON — Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor.
A pooled analysis of data from…